Lilly Ventures

Lilly Ventures has historically operated as Eli Lilly’s corporate venture arm, with later iterations rebranded under Lilly Asia Ventures and other vehicles depending on geography and vintage. Treat the entity primarily as a strategic biopharma investor rather than a financial generalist. Stage discipline runs from seed through later venture rounds for therapeutics, with checks typically in the $5M to $20M range, and the realistic founder fit is preclinical or clinical-stage drug development, novel modalities, and platform biotech with a credible licensing narrative. Digital health, devices, and AI software are out of scope unless they directly enable Lilly’s core therapeutic franchises in diabetes, oncology, immunology, or neurology. Geographic posture is global, with active capacity in the US, Europe, and Greater China through the Lilly Asia Ventures vehicle. The right founder profile is a scientific founder with credible academic pedigree, clean IP, and a willingness to engage with strategic capital. Entry path runs through Lilly’s external innovation and BD organizations rather than a generic partner inbox; warm introduction from a co-investing biotech VC or from a Lilly scientific contact dramatically increases response. Founders should arrive prepared for strategic alignment questions, including potential collaboration structures, and engage independent counsel before negotiating terms. For physician AI software founders, this is almost never the right name; for therapeutic founders inside Lilly’s strategic remit, it is among the most relevant strategic checks available.